1005 related articles for article (PubMed ID: 27208063)
1. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy.
Picarda E; Ohaegbulam KC; Zang X
Clin Cancer Res; 2016 Jul; 22(14):3425-3431. PubMed ID: 27208063
[TBL] [Abstract][Full Text] [Related]
2. New checkpoints in cancer immunotherapy.
Ni L; Dong C
Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
[TBL] [Abstract][Full Text] [Related]
3. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3.
Janakiram M; Shah UA; Liu W; Zhao A; Schoenberg MP; Zang X
Immunol Rev; 2017 Mar; 276(1):26-39. PubMed ID: 28258693
[TBL] [Abstract][Full Text] [Related]
4. B7-H3 immunoregulatory roles in cancer.
Mortezaee K
Biomed Pharmacother; 2023 Jul; 163():114890. PubMed ID: 37196544
[TBL] [Abstract][Full Text] [Related]
5. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
6. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity.
Loo D; Alderson RF; Chen FZ; Huang L; Zhang W; Gorlatov S; Burke S; Ciccarone V; Li H; Yang Y; Son T; Chen Y; Easton AN; Li JC; Rillema JR; Licea M; Fieger C; Liang TW; Mather JP; Koenig S; Stewart SJ; Johnson S; Bonvini E; Moore PA
Clin Cancer Res; 2012 Jul; 18(14):3834-45. PubMed ID: 22615450
[TBL] [Abstract][Full Text] [Related]
7. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
[TBL] [Abstract][Full Text] [Related]
8. Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.
Khan M; Arooj S; Wang H
Front Immunol; 2021; 12():651634. PubMed ID: 34531847
[TBL] [Abstract][Full Text] [Related]
9. Development of DS-5573a: A novel afucosylated mAb directed at B7-H3 with potent antitumor activity.
Nagase-Zembutsu A; Hirotani K; Yamato M; Yamaguchi J; Takata T; Yoshida M; Fukuchi K; Yazawa M; Takahashi S; Agatsuma T
Cancer Sci; 2016 May; 107(5):674-81. PubMed ID: 26914241
[TBL] [Abstract][Full Text] [Related]
10. B7-H3-mediated tumor immunology: Friend or foe?
Wang L; Kang FB; Shan BE
Int J Cancer; 2014 Jun; 134(12):2764-71. PubMed ID: 24013874
[TBL] [Abstract][Full Text] [Related]
11. B7-H3 on circulating epithelial tumor cells correlates with the proliferation marker, Ki-67, and may be associated with the aggressiveness of tumors in breast cancer patients.
Pizon M; Schott DS; Pachmann U; Pachmann K
Int J Oncol; 2018 Nov; 53(5):2289-2299. PubMed ID: 30226585
[TBL] [Abstract][Full Text] [Related]
12. Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase.
Aguilera TA; Giaccia AJ
Clin Cancer Res; 2017 Jun; 23(12):2928-2933. PubMed ID: 28289089
[TBL] [Abstract][Full Text] [Related]
13. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
[TBL] [Abstract][Full Text] [Related]
14. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors.
Majzner RG; Theruvath JL; Nellan A; Heitzeneder S; Cui Y; Mount CW; Rietberg SP; Linde MH; Xu P; Rota C; Sotillo E; Labanieh L; Lee DW; Orentas RJ; Dimitrov DS; Zhu Z; Croix BS; Delaidelli A; Sekunova A; Bonvini E; Mitra SS; Quezado MM; Majeti R; Monje M; Sorensen PHB; Maris JM; Mackall CL
Clin Cancer Res; 2019 Apr; 25(8):2560-2574. PubMed ID: 30655315
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy.
Zhao B; Li H; Xia Y; Wang Y; Wang Y; Shi Y; Xing H; Qu T; Wang Y; Ma W
J Hematol Oncol; 2022 Oct; 15(1):153. PubMed ID: 36284349
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
[TBL] [Abstract][Full Text] [Related]
17. B7-H3: An Attractive Target for Antibody-based Immunotherapy.
Kontos F; Michelakos T; Kurokawa T; Sadagopan A; Schwab JH; Ferrone CR; Ferrone S
Clin Cancer Res; 2021 Mar; 27(5):1227-1235. PubMed ID: 33051306
[TBL] [Abstract][Full Text] [Related]
18. Humanized Affinity-matured Monoclonal Antibody 8H9 Has Potent Antitumor Activity and Binds to FG Loop of Tumor Antigen B7-H3.
Ahmed M; Cheng M; Zhao Q; Goldgur Y; Cheal SM; Guo HF; Larson SM; Cheung NK
J Biol Chem; 2015 Dec; 290(50):30018-29. PubMed ID: 26487718
[TBL] [Abstract][Full Text] [Related]
19. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
[TBL] [Abstract][Full Text] [Related]
20. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy.
Yang S; Wei W; Zhao Q
Int J Biol Sci; 2020; 16(11):1767-1773. PubMed ID: 32398947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
